FDA Approves Breyanzi®—A New Biologic for Treating Large B-Cell Lymphoma
On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed or refractory large B-cell lymphoma.”